The BCR-ABL qualitative test is a PCR-based assay that detects the BCR‑ABL fusion gene (Philadelphia chromosome) in blood or bone marrow. It determines presence or absence of BCR‑ABL mRNA, helping diagnose chronic myeloid leukemia and some acute lymphoblastic leukemias. As a qualitative test it gives a positive/negative result; quantitative PCR is used to measure disease burden and treatment response.

BCR-ABL1 positive means a fusion gene (the Philadelphia chromosome) is detected in blood or bone marrow. The BCR-ABL1 protein is an abnormal tyrosine kinase that drives uncontrolled white blood cell growth, commonly seen in chronic myeloid leukemia and some acute lymphoblastic leukemias. Detection confirms diagnosis, guides use of targeted tyrosine kinase inhibitors, and allows molecular monitoring of treatment response.

BCR‑ABL quantitative PCR is reported on the International Scale (IS). A “normal” (negative) result is undetectable BCR‑ABL transcripts. Major molecular response (MMR) is ≤0.1% IS (3‑log reduction). Deeper responses: MR4 ≤0.01% IS (4‑log) and MR4.5 ≤0.0032% IS (4.5‑log). Newly diagnosed baseline is standardized as 100% IS. Interpretation depends on assay sensitivity and lab conversion; discuss with your hematologist.

BCR‑ABL negative means the test did not detect the Philadelphia chromosome fusion gene. That makes Philadelphia‑positive chronic myeloid leukemia or ALL less likely, or — if you were previously positive and treated — suggests molecular remission. Results depend on test sensitivity; very low levels can be missed or another abnormality may exist. Follow‑up testing and hematology consultation are recommended.

CML (chronic myeloid leukemia) can be serious but is often controllable. It's a blood cancer that, untreated, can progress to aggressive stages. Modern targeted therapies (tyrosine kinase inhibitors) commonly induce long remissions and allow many people to live near‑normal lives, though lifelong monitoring and adherence are usually required. Early diagnosis and regular follow‑up improve outcomes.

Most CML patients (the vast majority) have the BCR‑ABL1 fusion gene or the Philadelphia chromosome, which drives the disease and guides targeted therapy. However, a small subset of patients are BCR‑ABL‑negative; these cases are classified as atypical CML or other myeloproliferative neoplasms and have different features and treatment approaches. Diagnosis relies on molecular testing to detect BCR‑ABL.